| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
123.51(B) |
| Last
Volume: |
1,112,262 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
34,832 |
156,170 |
271,197 |
631,666 |
| Total Sell Value |
$15,561,839 |
$65,781,555 |
$107,325,701 |
$215,119,054 |
| Total People Sold |
10 |
13 |
14 |
18 |
| Total Sell Transactions |
12 |
45 |
68 |
135 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$3,206,563 |
D/D |
(13,308) |
57,002 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-10 |
4 |
D |
$240.95 |
$8,856,117 |
D/D |
(36,755) |
180,063 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$1,125,959 |
D/D |
(4,673) |
25,550 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$2,943,204 |
D/D |
(12,215) |
59,268 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$2,154,575 |
D/D |
(8,942) |
58,621 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-02-07 |
4 |
AS |
$234.84 |
$475,643 |
D/D |
(2,000) |
1,875 |
|
16% |
|
| Lee Yuchun |
Director |
– • – |
2020-02-07 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-02-06 |
4 |
AS |
$238.71 |
$479,017 |
D/D |
(2,000) |
1,875 |
|
17% |
|
| Lee Yuchun |
Director |
– • – |
2020-02-06 |
4 |
OE |
$57.27 |
$114,540 |
D/D |
2,000 |
3,875 |
|
- |
|
| Kewalramani Reshma |
EVP and CMO |
• – – |
2020-02-06 |
4 |
AS |
$238.76 |
$496,600 |
D/D |
(2,074) |
35,285 |
|
17% |
|
| Kewalramani Reshma |
EVP and CMO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$372,638 |
D/D |
2,074 |
37,359 |
|
- |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-06 |
4 |
AS |
$238.77 |
$231,527 |
D/D |
(967) |
16,946 |
|
17% |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$168,302 |
D/D |
967 |
17,913 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
AS |
$238.74 |
$604,775 |
D/D |
(2,526) |
70,310 |
|
17% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$434,614 |
D/D |
2,526 |
72,836 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-06 |
4 |
AS |
$238.71 |
$667,253 |
D/D |
(2,787) |
67,563 |
|
17% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$483,559 |
D/D |
2,787 |
70,350 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-06 |
4 |
AS |
$238.77 |
$604,783 |
D/D |
(2,526) |
68,246 |
|
17% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$434,614 |
D/D |
2,526 |
70,772 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-06 |
4 |
AS |
$238.73 |
$111,523 |
D/D |
(466) |
30,223 |
|
17% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-02-06 |
4 |
OE |
$187.53 |
$87,389 |
D/D |
466 |
30,689 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2020-02-05 |
4/A |
A |
$0.00 |
$0 |
D/D |
110,472 |
216,818 |
|
- |
|
| Kewalramani Reshma |
EVP and CMO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
22,187 |
35,285 |
|
- |
|
| Wagner Charles F Jr |
EVP and CFO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,021 |
17,816 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
35,293 |
71,483 |
|
- |
|
3280 Records found
|
|
Page 27 of 132 |
|
|
4.77 (1.01%) 
